Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 15/20 | 0.67 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.63 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.63 |
| ▸ | JAK2 | O60674 | 2/20 | 0.59 |
| ▸ | DKK1 | O94907 | 1/20 | 0.59 |
| ▸ | GSK3B | P49841 | 1/20 | 0.59 |
| ▸ | CHUK | O15111 | 2/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3518099 | 0.96 | IKBKB (0.64) | IKBKBMAPK8MAPK10JAK2DKK1 | |
| SCHEMBL3519410 | 0.82 | IKBKB (0.79) | IKBKBMAPK8MAPK10JAK2DKK1 | |
| SCHEMBL3516817 | 0.81 | IKBKB (0.69) | IKBKBMAPK8MAPK10JAK2DKK1 | |
| SCHEMBL3516707 | 0.81 | IKBKB (0.78) | IKBKBMAPK8MAPK10JAK2DKK1 | |
| SCHEMBL3519764 | 0.81 | IKBKB (0.97) | IKBKBMAPK8MAPK10JAK2DKK1 | |
| SCHEMBL3522035 | 0.80 | IKBKB (0.68) | IKBKBMAPK8MAPK10JAK2DKK1 | |
| SCHEMBL3518049 | 0.79 | IKBKB (0.79) | IKBKBMAPK8MAPK10JAK2DKK1 | |
| SCHEMBL3520622 | 0.79 | IKBKB (0.79) | IKBKBMAPK8MAPK10JAK2DKK1 | |
| SCHEMBL3516622 | 0.79 | IKBKB (1.00) | IKBKBMAPK8MAPK10JAK2DKK1 | |
| SCHEMBL3519939 | 0.79 | IKBKB (1.00) | IKBKBMAPK8MAPK10JAK2DKK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | claimed |
| CN-101039919-A | N-benzenesulfonyl substituted anilino-pyrimidine analogs | WYETH CORP (US) | 2007-09-19 | — | — | CN | claimed |
| US-20060079543-A1 | Anilino-pyrimidine analogs | WYETH (US) | 2006-04-13 | — | — | US | claimed |
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | disclosed |
| CN-101039919-A | N-benzenesulfonyl substituted anilino-pyrimidine analogs | WYETH CORP (US) | 2007-09-19 | — | — | CN | disclosed |
| US-20060079543-A1 | Anilino-pyrimidine analogs | WYETH (US) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079543-A1 | Anilino-pyrimidine analogs | DPYD, TYMP, ADORA3 | IKBKB 3246/4885MAPK8 3605/4885MAPK10 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.